Aug 10 (Reuters) - ViroPharma Inc. said (VPHM.O: Quote, Profile, Research) said it and partner Wyeth Pharmaceuticals, a unit of Wyeth (WYE.N: Quote, Profile, Research), decided to end dosing with a drug to treat Hepatitis C virus (HCV) in a mid-stage trial due to safety concerns.
Exton, Pennsylvania-based ViroPharma said the U.S. Food and Drug Administration has been notified that all patients on triple therapy will now be maintained on only pegylated interferon and ribavirin for the remainder of the clinical study.
read more
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment